ArticlePsychopharmacology2026
Schaftoside inhibits neuroinflammation and exerts antidepressant effects through METTL3-mediated m6A modification of circ_0001470 sponging miR-183-5p to regulate MAP3K1 expression.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMajor depressive disorder (MDD) involves neuroinflammation and dysregulation of non-coding RNAs ; however, effective targeted therapies remain limited. This study investigated the antidepressant effects and molecular mechanisms of the flavonoid schaftoside.
methodsDepression-like behaviors were assessed using sucrose preference test, open field test, and elevated plus maze test. Levels of the proinflammatory cytokines (TNF-α, IL-1β, IL-6) were measured in hippocampal tissue. Whole-transcriptome sequencing were performed to identify differentially expressed mRNAs, miRNAs and circRNAs followed by construction of a competing endogenous RNA (ceRNA) network. The interaction between circ_0001470 and miR-183-5p was validated through co-transfection and dual-luciferase assays. MeRIP-seq was conducted on mouse hippocampus tissue, and an LPS-induced inflammatory model was established in BV-2 cells. m6A methylation levels of relevant genes were assessed using m6A-IP-qPCR.
resultsSchaftoside treatment significantly ameliorated depressive-like behaviors in CUMS-induced mice and reduced hippocampal levels of the proinflammatory cytokines TNF-α, IL-1β, and IL-6. Transcriptome identified 421 mRNAs, 29 miRNAs, and 51 circRNAs were altered in response to schaftoside, with the MAPK signaling pathway emerging as a key regulatory pathway. CeRNA and cellular analysis and cellular assay confirmed that circ_0001470 functions as a sponge for miR-183-5p, thereby regulating its downstream target MAP3K1. In LPS-treated BV-2 cells, both METTL3 expression and m6A methylation of circ_0001470 were increased. Treatment with the METTL3 inhibitor STM2457 effectively suppressed METTL3 expression and reduced m6A levels on circ_0001470. Schaftoside was found to inhibits METTL3, decrease m6A modification of circ_0001470, and block subsequent inflammatory cascades.
conclusionsThese findings demonstrated for the first time that schaftoside alleviates neuroinflammation by regulating METTL3-mediated m6A modification of circ_0001470, which in turn sponges miR-183-5p to modulate MAP3K1 expression. This work provide new insights into potential therapeutic strategies for MDD.
Indexed as
Identifiers
41870533What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.